Phytopharm plc Stock London S.E.
Stocks
GB0006869720
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 07-13 | Oil rises as Iran escalation keeps FTSE subdued | AN |
| 07-13 | Ixico notes ending of Huntington's disease programmes | AN |
| Market Cap | 17.99M 24.26M 21.21M 19.57M 34.08M 2.33B 34.67M 234M 91.67M 1.14B 91.12M 89.12M 3.93B | P/E 2026 * |
-5.89x | P/E 2027 * | -6.35x |
|---|---|---|---|---|---|
| Enterprise Value | 7.79M 10.51M 9.19M 8.47M 14.76M 1.01B 15.01M 101M 39.69M 494M 39.45M 38.59M 1.7B | EV / Sales 2026 * |
0.97x | EV / Sales 2027 * | 1.32x |
| Free-Float |
89.25% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Phytopharm plc
| Manager | Title | Age | Since |
|---|---|---|---|
Bram Goorden
CEO | Chief Executive Officer | 53 | 19/08/2024 |
Grant Nash
DFI | Director of Finance/CFO | 50 | 21/08/2019 |
Mark Austin
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Warne
CHM | Chairman | 51 | - |
Grant Nash
BRD | Director/Board Member | 50 | 21/08/2019 |
Katherine Rogers
BRD | Director/Board Member | 60 | 21/01/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.53% | -1.68% | +0.53% | +5.84% | 50.35B | |
| -2.01% | -5.13% | +372.19% | +581.40% | 39.21B | |
| +2.00% | +0.95% | +32.98% | -4.70% | 34.52B | |
| +1.81% | +5.28% | +14.21% | +61.10% | 34.6B | |
| +0.06% | -0.57% | +3.35% | +27.42% | 27.05B | |
| -1.51% | -3.61% | - | - | 16.68B | |
| +1.31% | -0.25% | +69.66% | +115.94% | 15.11B | |
| +0.29% | +0.78% | +14.69% | +18.05% | 13.85B | |
| -0.60% | +1.49% | +18.92% | -30.10% | 13.18B | |
| Average | -0.06% | +0.81% | +65.82% | +96.87% | 27.17B | |
| Weighted average by Cap. | -0.12% | +0.70% | +78.32% | +120.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8M 10.79M 9.43M 8.7M 15.16M 1.04B 15.42M 104M 40.77M 507M 40.52M 39.63M 1.75B | 9M 12.14M 10.61M 9.79M 17.05M 1.17B 17.34M 117M 45.86M 571M 45.59M 44.59M 1.97B |
| Net income | -2.14M -2.89M -2.53M -2.33M -4.06M -278M -4.13M -27.83M -10.92M -136M -10.85M -10.62M -469M | -2.8M -3.78M -3.3M -3.05M -5.31M -364M -5.4M -36.38M -14.27M -178M -14.19M -13.88M -612M |
| Net Debt | -10.2M -13.76M -12.03M -11.1M -19.33M -1.32B -19.66M -132M -51.98M -647M -51.67M -50.53M -2.23B | -6.1M -8.23M -7.19M -6.64M -11.56M -792M -11.76M -79.22M -31.08M -387M -30.9M -30.22M -1.33B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
